Neoadjuvant therapy for HER2-positive breast cancer
The human epidermal growth receptor 2 (HER2, c-erb-B2) is present in 15-20% of breast cancer at the time of diagnosis. Overexpression of HER2 receptor is associated with more aggressive form of breast cancer. Trastuzumab is a human monoclonal antibody that blocks the signaling pathways of cell prol...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Bosnian |
| Published: |
University of East Sarajevo
2019-06-01
|
| Series: | Biomedicinska istraživanja |
| Subjects: | |
| Online Access: | http://www.biomedicinskaistrazivanja.com/wp-content/uploads/2019/06/10a-Dukic.pdf |